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Hyperglycemia resulting from uncontrolled glucose regulation is widely recognized as the causal link between diabetes and diabetic
complications. Four major molecular mechanisms have been implicated in hyperglycemia-induced tissue damage: activation of protein kinase C
(PKC) isoforms via de novo synthesis of the lipid second messenger diacylglycerol (DAG), increased hexosamine pathway flux, increased
advanced glycation end product (AGE) formation, and increased polyol pathway flux. Hyperglycemia-induced overproduction of superoxide is
the causal link between high glucose and the pathways responsible for hyperglycemic damage. In fact, diabetes is typically accompanied by
increased production of free radicals and/or impaired antioxidant defense capabilities, indicating a central contribution for reactive oxygen species
(ROS) in the onset, progression, and pathological consequences of diabetes. Besides oxidative stress, a growing body of evidence has
demonstrated a link between various disturbances in mitochondrial functioning and type 2 diabetes. Mutations in mitochondrial DNA (mtDNA)
and decreases in mtDNA copy number have been linked to the pathogenesis of type 2 diabetes. The study of the relationship of mtDNA to type 2
diabetes has revealed the influence of the mitochondria on nuclear-encoded glucose transporters, glucose-stimulated insulin secretion, and nuclear-
encoded uncoupling proteins (UCPs) in β-cell glucose toxicity. This review focuses on a range of mitochondrial factors important in the
pathogenesis of diabetes. We review the published literature regarding the direct effects of hyperglycemia on mitochondrial function and suggest
the possibility of regulation of mitochondrial function at a transcriptional level in response to hyperglycemia. The main goal of this review is to
include a fresh consideration of pathways involved in hyperglycemia-induced diabetic complications.
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The number of adults with clinical diagnosis of diabetes has
been increasing dramatically worldwide. It has been estimated
that the number of adults affected by diabetes in the world will
grow from 135 million in 1995 to 300 million in the year 2025.
Prevalence of diabetes is higher in developed than in developing
countries, but the major increase in people with diabetes will
occur in developing countries. India, China, and the U.S. are
currently the countries with the largest number of people with
diabetes. The majority of people with diabetes in developing
and developed countries are in the age range of 45–64 and 65
years, respectively. There are more women than men with
diabetes, especially in developed countries (King et al., 1998).
Diabetes mellitus has been classified in two forms. Type 1
diabetes, which accounts for about 10% of all cases of diabetes,
is caused by autoimmune destruction of pancreatic β-cells,
producing insulin deficiency. Type 2 diabetes, the more
prevalent form of diabetes, is considered a heterogeneous
disease due to the multiplicity of factors that cause the observed
phenotype. It results from the combination of insulin resistance
and/or a β-cell secretory defect. An explosive increase in the
prevalence of type 2 diabetes is predicted for the future. Some
16 million to 17 million people have the condition, and an equal
number are thought to be “prediabetic”, having early symptoms
but not yet the full manifestation of the disease. Even children
are no longer exempt to develop type 2 diabetes that until
recently rarely affected people before middle age (Marx, 2002).
In the U.S., about 30% of all new cases of diabetes are children
with diabetes type 2.
Diabetes mellitus is a metabolic disorder characterized by
hyperglycemia and insufficiency of secretion or receptor
insensitivity to endogenous insulin. While exogenous insulin
and other medications can control many aspects of diabetes,
assorted complications affecting the vascular system, kidney,
and peripheral nerves are common and extremely costly in
terms of longevity and quality of life. Not surprisingly, diabetesFig. 1. Hyperglycemia-induced ROS generation and consequent activation of path
acetylglucosamine; PAI, plasminogen activator inhibitor; TGF-β, transforming growhas a marked influence on cardiac metabolism due to altered
substrate supply, impaired insulin action, and metabolic (mal)
adaptations in the diabetic heart. Liver is a key organ in the
maintenance of systemic glucose homeostasis in mammals. The
liver regulates blood glucose levels within a very narrow range
under various nutritional conditions, directing excess glucose
immediately following a meal to various storage forms and
providing glucose to the systemic circulation to fuel the
function of many organs and tissues in the fasting state and
under conditions of food deprivation.
Pathological pathways for glucose toxicity—mitochondrial
factors in the pathogenesis of diabetes
Hyperglycemia resulting from uncontrolled glucose regula-
tion is widely recognized as the causal link between diabetes
and diabetic complications (Giardino et al., 1996; Brownlee,
2001). Brief episodes of hyperglycemia cause tissue damage by
mechanisms involving repeated acute changes in cellular
metabolism. However, exposure to high glucose also causes
cumulative changes in long-lived macromolecules, which
persist despite restoration of euglycemia.
A large amount of data emphasize four key metabolic
pathways as being major contributors to hyperglycemia-
induced cell damage (Fig. 1) (Nishikawa et al., 2000a;
Brownlee, 2001; Robertson, 2004): (1) increased polyol
pathway flux; (2) increased advanced glycation end product
(AGE) formation; (3) activation of protein kinase C (PKC)
isoforms; and (4) increased hexosamine pathway flux. Hyper-
glycemia results in increased enzymatic conversion of glucose
to the polyalcohol sorbitol, with concomitant decreases in
NADPH and glutathione (Brownlee, 2001). The resulting loss
of antioxidant reducing equivalents results in enhanced
sensitivity to oxidative stress associated with intracellular
ROS. Hyperglycemia-induced overproduction of superoxide
significantly inhibits glucose-6-phosphate dehydrogenase
(Nishikawa et al., 2000a), the rate-limiting enzyme of theological pathways (___, direct role; -----, indirect role). GlcNac, O-linked N-
th factor-β.
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reducing equivalents to the antioxidant defense system. The
product, NADPH, is the cell's principal reductant (Zhang et al.,
2000; Wu et al., 2001) and is required for providing reducing
equivalents to the glutathione peroxidase–glutathione reductase
system (Fig. 2). Additionally, sorbitol is metabolized to fructose
by sorbitol dehydrogenase (Fig. 2), increasing the ratio NADH/
NAD+ (Brownlee, 2001). This results in oxidized triose
phosphates with de novo synthesis of diacylglycerol (DAG).
Increased DAG content activates protein kinase C (Fig. 2),
responsible for several pathologies of diabetic complications
(Brownlee, 2001).
AGEs have been implicated in the pathogenesis of the
major microvascular complications of diabetes mellitus:
nephropathy, neuropathy, and retinopathy (Basta et al., 2004;
Cooper, 2004; Stitt et al., 2004). Glucose, although one of the
least reactive reducing sugars, can react with a free amino
group to form an adduct commonly referred as a Schiff base.
In a Schiff base, the aldehydic carbon–oxygen double bond of
the sugar is converted to a carbon–nitrogen double bond with
the amine. Formation of the Schiff base is relatively fast and
highly reversible. Subsequent rearrangement of the Schiff base
originates an Amadori product. This reaction, which is
believed to occur via an intermediate, open chain enol form,
is much faster than the reverse reaction (Ulrich and Cerami,
2001). Consequently, the Amadori glycation product tends to
accumulate on proteins, initiating the processes of advanced
glycation. AGEs arise from autooxidation of glucose to
glyoxal, decomposition of the Amadori product to 3-
deoxyglucosone, and fragmentation of glyceraldehyde-3-
phosphate and dihydroxyacetone phosphate to methylglyoxal
(Brownlee, 1994). Glyoxal, methylglyoxal, and 3-deoxyglu-
cosone are reactive intracellular dicarbonyl that react withFig. 2. Mechanisms of hyperglycemia-induced damage. AEGs, advancedamino groups of intracellular and extracellular proteins to form
AGEs. Production of intracellular AGE precursors interferes
with target cell integrity by modifying protein function or by
inducing receptor-mediated production of reactive oxygen
species, which have been shown to cause changes in gene
expression (Yan et al., 1994).
The hexosamine biosynthesis pathway is an additional
pathway of glucose metabolism that may mediate some of the
toxic effects of glucose (Du et al., 2000; Brownlee, 2001). Under
usual metabolic conditions, 2–5% of glucose entering cells is
directed into the hexosamine pathway, beginning with the
conversion of fructose 6-phosphate to glucosamine 6-phosphate
by the rate-limiting enzyme glutamine:fructose-6-phosphate
amidotransferase (Fig. 2) (James et al., 2002). Because
hyperglycemia-induced overproduction of superoxide signifi-
cantly inhibits glyceraldehyde-3-phosphate dehydrogenase ac-
tivity (Du et al., 2000), this inhibition would activate all the
pathways of hyperglycemic damage by diverting upstream
glycolytic metabolites into these signaling pathways. During
hyperglycemia, because of the increased nutrient availability,
much of the excess glucose is shunted into the hexosamine
pathway. The end product of this pathway, UDP-N-acetylglu-
cosamine, is the substrate for the glycosylation of important
intracellular factors (McClain and Crook, 1996) including
transcription factors, thereby affecting the expression of many
genes including plasminogen activator inhibitor-1 (PAI-1) and
leads to the development of the microvascular complications of
diabetes (Gabriely et al., 2002; Goldberg et al., 2002).
Until recently, there was no unifying hypothesis linking these
four mechanisms. It has been shown that hyperglycemia-
induced overproduction of superoxide by mitochondria (Fig.
1) is the trigger that drives each of these pathways (Du et al.,
2000; Nishikawa et al., 2000b; Brownlee, 2001).glycation end products, DAG, diacylglycerol; PKC, protein kinase C.
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Mitochondria are the principal source of ROS in cells as the
result from imperfectly coupled electron transport. Oxidative
stress is widely accepted as playing a key mediatory role in the
development and progression of diabetes and its complications
due to increased production of free radicals and impaired
antioxidant defenses (Ha and Lee, 2000; Bonnefont-Rousselot,
2002; Evans et al., 2003; Ceriello, 2003; Maritim et al., 2003).
Pyruvate derived from glycolysis is transported into the
mitochondria, where it is oxidized by the tricarboxylic acid
(TCA) cycle to generate NADH. Electrons deriving from
oxidation of substrates are funneled through the redox carriers
of the respiratory chain (complexes I, III, and IV) to the final
electron acceptor, molecular oxygen. Through four-electron
reduction, oxygen is converted to water. However, during
normal metabolism, reactive incompletely reduced forms of
oxygen, such as superoxide (Fig. 3), are produced. Normally,
only 0.1% of total oxygen consumption leaks from the
respiratory chain to generate ROS.
The primary factor governing mitochondrial ROS generation
is the redox state of the respiratory chain (Skulachev, 1996;
Lambert and Brand, 2004a). Electron transfer through the
mitochondrial respiratory chain generates a proton (voltage)
gradient. Under normal conditions, much of the energy of this
voltage gradient is used to generate ATP as the collapse of the
proton gradient through ATP synthase drives the ATP synthetic
machinery. The amplitude of the electrochemical proton
gradient, which is known as respiratory control, regulates the
overall rate of electron transport in the respiratory chain. When
the electrochemical potential difference generated by the proton
gradient is high (such as in high glucose states), the life of
superoxide-generating electron transport intermediates, such as
ubisemiquinone, is prolonged. This occurs because the activityFig. 3. Electron transport chain ROS generation by mitochondria and dissipation of th
prevent oxidative stress in hyperglycemia. CI, complex I; CII, complex II; CIII, comp
uncoupling protein.of the respiratory chain complexes as proton pumps is
inherently governed by the transmembrane proton gradient
(ΔpH) and the membrane potential (Δ¥mt). When sufficiently
high, ΔpH and Δ¥mt inhibit the proton pumps (Starkov and
Fiskum, 2003). It is evident that each of the ROS-generating
sites has a different redox potential, and thus each will respond
differently to changes in ΔpH and Δ¥mt, resulting in a complex
regulation of ROS generation by these membrane gradients
(Lambert and Brand, 2004b). There appears to be a threshold
value above which even a small increase in Δ¥mt gives rise to a
large stimulation of superoxide production by mitochondria
(Korshunov et al., 1997; Bodrova et al., 1998). Overall, most
bioenergetic effectors, via their effects on ΔpH and Δ¥mt, can
modulate mitochondrial ROS generation. In isolated mitochon-
dria, dissipation of membrane potential by chemical uncouplers,
free fatty acids, or the presence of ADP decreases the rate of
ROS generation.
How is ROS production via the mitochondrial respiratory
chain a causal link between high glucose and the main pathways
responsible for hyperglycemic damage? The prevailing hypoth-
esis is that hyperglycemia-induced increase in electron transfer
donors (NADH and FADH2) increases electron flux through the
mitochondrial electron transport chain. Consequently, there is
an increase of the ATP/ADP ratio and hyperpolarization of the
mitochondrial membrane potential. This high electrochemical
potential difference generated by the proton gradient leads to
partial inhibition of the electron transport in complex III,
resulting in an accumulation of electrons to coenzyme Q. In
turn, this drives partial reduction of O2 to generate the free
radical anion superoxide (Nishikawa et al., 2000b; Brownlee,
2001). It is this accelerated reduction of coenzyme Q and
generation of ROS that is believed to be the fundamental source
for mitochondrial dysfunction that plays a critical role in
diabetes-related metabolic disorders and tissue histopathology.e proton gradient by UCPs. Scavenging by antioxidant defenses is insufficient to
lex III; CIV, complex IV; CV, ATPsynthase; TCA, tricarboxylic acid cycle; UCP,
171A.P. Rolo, C.M. Palmeira / Toxicology and Applied Pharmacology 212 (2006) 167–178Nishikawa and colleagues showed that, in bovine aortic
endothelial cells exposed to high glucose, addition of CCCP
(an uncoupler of oxidative phosphorylation that abolishesΔ¥mt)
decreases ROS production (Nishikawa et al., 2000b). Russell
and colleagues also demonstrated that high glucose-generated
ROS is coupled with hyperpolarization of Δ¥mt in neurons
(Russell et al., 2002).
Mitochondrial uncoupling proteins in type 2 diabetes
UCPs are members of a family of nuclear-encoded
mitochondrial carriers, which act as proton carrier proteins in
the mitochondrial inner membrane. This facilitates the proton
leak across the membrane (Fig. 3), able to modulate the
coupling between the respiratory electron transport chain and
ATP synthesis. UCP-induced proton leakiness causes partial
depolarization of the mitochondrial transmembrane potential
(Dullo and Samec, 2001).
The UCP subtypes, UCP-1, UCP-2, and UCP-3, differ
with respect to tissue distribution and probably also function.
Increased induction UCP-1 leads to thermogenesis. The
functions of UCP-2 and UCP-3 are still unclear but are
believed to cause a mild uncoupling of respiration that
governs mitochondrial membrane potential and the accumu-
lation of oxygen radicals and/or control of the NAD+/NADH
ratio. A number of laboratories have demonstrated that UCP-
2 expression is inversely correlated with the level of ROS
generation by respiring mitochondria (Nègre-Salvayre et al.,
1997; Skulachev, 1998). In the context of diabetes, over-
expression of UCPs in cultured neurons blocks glucose-
induced programmed cell death by preventing mitochondrial
hyperpolarization and formation of ROS (Vincent et al.,
2004). This suggests a central role for UCPs in the
regulation of mitochondrial membrane hyperpolarization
and ROS formation in glucose-mediated neuronal injury. β-
cells subjected to oxidative stress were found to combat
H2O2 toxicity through the induction of UCP-2 (Li et al.,
2001). Additionally, muscle cells overexpressing UCP-3 were
shown a significant decrease in mitochondrial ROS produc-
tion, although there were no differences in glucose oxidation
and mitochondrial membrane potential (MacLellan et al.,
2005).
Besides reduction of mitochondrial ROS generation, UCPs
play a key role in determining the relationship in regulating fatty
acid and glucose oxidation (Boss et al., 2000). The observation
that UCP-3 was upregulated in type 2 diabetic rat hearts
supports a regulatory role for UCPs in fatty acid oxidation.
UCP-3 is proposed to export fatty acid out of mitochondria to
permit continued high rates of fatty acid oxidation under
conditions of fatty acid over-supply. UCP-3 may also act as a
“flipase” to protect mitochondria from potentially damaging
fatty acids (Carley and Severson, 2005). As impaired fatty acid
metabolism and ROS handling are important precursors in
muscular insulin resistance, UCPs appear as possible therapeu-
tic targets in type 2 diabetes (Langin, 2003). Indeed, decreased
UCP-3 content is associated with insulin resistance in muscle of
prediabetic and diabetic individuals, although with no clearexplanation for UCP-3 function (Schrauwen et al., 2001). Mice
overexpressing UCP-1 display enhanced skeletal muscle
glucose transport, despite decreased ATP content and mito-
chondrial proteins (Han et al., 2004). In high-fat-diet-induced
diabetes, hepatic UCP-1 expression markedly improved insulin
resistance (Ishigaki et al., 2005). However, the perspective of
UCPs as a therapeutic approach has to be carefully addressed. In
fact, excessive proton leak will induce mitochondrial uncou-
pling and subsequent impairment of cell bioenergetics.
Furthermore, these observations cannot be generalized for all
tissues. It has been described that upregulation of UCP-2 in
pancreatic β-cells is associated with decreased ATP production,
closure of ATP-sensitive K+ channels, and impairment of
glucose-stimulated insulin secretion (Brownlee, 2003; Lowell
and Shulman, 2005). Lack of UCP-2 dramatically improves
insulin secretion and decreases hyperglycemia in leptin-
deficient mice (Langin, 2003).
Mitochondrial function in diabetes
Impairment of mitochondrial function is intrinsically
related with diabetes. The observation that reduced rates of
ATP synthesis in subjects with a family history of diabetes
occur before the onset of impaired glucose tolerance
(Petersen et al., 2004) indicates the significance of
mitochondrial dysfunction in diabetes progression. Goto–
Kakizaki (GK) rat and streptozotocin (STZ)-treated rat are
models for diabetes type 2 and diabetes type 1, respectively.
These models have been used to study several aspects of
mitochondrial bioenergetics and function in diabetic states.
Parameters such as oxygen consumption, transmembrane
potential, calcium loading capacity, resistance or susceptibil-
ity to oxidative stress, and the mitochondrial permeability
transition (MPT) have been addressed.
Metabolic alterations in liver mitochondria were evaluated in
both models, at initial and advanced states of disease. The
observed mitochondrial alterations as a function of age are
different in both models (GK rats and STZ-treated rats),
indicating differential adaptation mechanisms to counteract
high glucose levels typical of the disease (Ferreira et al., 1999b,
2003). Mitochondria isolated from liver of 9 weeks type 1
diabetic rat showed decreased respiratory chain activity,
characterized by decreased membrane potential and respiratory
ratios. In contrast, liver mitochondria from 6 months GK rats
presented increased respiratory ratios. Additionally, the increase
in the repolarization rate and ATPase activity observed in GK
rats is presumably related to an improved efficiency of F0F1-
ATPase. Titrations with oligomycin, an inhibitor of the ATP
synthase, indicated that diabetic GK liver mitochondria require
excess oligomycin pulses to completely abolish phosphoryla-
tion, relative to control mitochondria. This suggests that liver
mitochondria of diabetic GK rats are provided with extra
catalytic units relative to control mitochondria of normal rats
(Palmeira et al., 1999). Such early adaptive responses of
mitochondrial function to diabetic stress may reflect changes in
gene expression induced by hyperglycemia as a mechanism for
cell adaptation to glucose toxicity.
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lipid peroxidation, which was correlated with an increase in
mitochondrial vitamin E (α-tocopherol) content and GSH/
GSSG ratio. Moreover, glutathione reductase activity was
significantly increased, whereas the glutathione peroxidase
was decreased in diabetic animals. Superoxide dismutase
activity was unchanged (Ferreira et al., 1999a). In GK rats,
mitochondria isolated from brain were more susceptible to in
vitro oxidative damage than brain mitochondria from normal
rats. This decreased susceptibility was inversely related to
their α-tocopherol and coenzyme Q (CoQ) content (Santos
et al., 2001). Thus, the difference in the antioxidant defense
mechanisms in brain and liver mitochondria of GK rats may
correspond to different adaptive responses of the cells to the
increased oxidative stress in diabetes. Testis mitochondrial
preparations from GK exhibited lower susceptibility to lipid
peroxidation, with increased mitochondrial glutathione and
coenzyme Q9 contents, whereas vitamin E was not changed
(Palmeira et al., 2001). This indicates a role for mitochon-
dria in the association between diabetes mellitus and
impairment of testicular function, ultimately leading to
reduced fertility.
Both types of diabetes affected negatively cardiac mito-
chondrial bioenergetics (Santos et al., 2003; Oliveira et al.,
2004). Reduced mitochondrial calcium uptake was observed in
heart mitochondria from STZ-treated rats. This was related with
enhanced susceptibility to MPT induction rather than damage to
the calcium uptake machinery (Oliveira et al., 2003). Interest-
ingly, heart mitochondria from GK rats were less susceptible to
the induction of MPT, showing larger calcium accumulation
before the overall loss of mitochondrial impermeability
(Oliveira et al., 2001). Different antioxidant approaches
(vitamin E or coenzyme Q10) administration in GK rats
showed no success in reversing the diabetic phenotype (Oliveira
et al., 2004).
Transcriptional regulatory circuits in diabetes
Each mitochondrion contains 2–10 copies of circular,
supercoiled, double-stranded DNA found unprotected within
the inner mitochondrial membrane. The close proximity of
mtDNA to ROS-generating sites makes mtDNA more vulner-
able to oxidative damage. The increase in oxidative stress
during hyperglycemia may thus lead to mutations in mtDNA
(Maassen et al., 2004). In fact, it has been estimated that 0.1–
9.0% of the diabetic population is due to a mutation in mtDNA
(Lamson and Plaza, 2002). Maternally inherited type 2 diabetes
was one of the first mitochondrially inherited diabetic
conditions to be identified (Ballinger et al., 1992). mtDNA
depletion has also been suggested as causative factor in diabetes
pathogenesis. Mitochondria of β-cells from GK rats were
shown to have decreased volume and mtDNA content, although
an increased number of mitochondria per unit area in the islet
tissue (Serradas et al., 1995). Alterations in mitochondrial
biogenesis in insulin-resistant relatives of type 2 diabetes have
also been observed. Prediabetic patients were found to have
significant mtDNA depletion before the onset of disease (Lee etal., 1998). mtDNA content has also been shown to affect the
expression of nuclear-encoded glucose transporters (Park et al.,
2001).
The majority of mitochondrial proteins are synthesized in the
nucleus and shuttled to the mitochondria. Only 13 proteins
involved with oxidative phosphorylation are exclusively
encoded by mtDNA. Since mitochondrial number and function
require both nuclear and mitochondrial-encoded genes, coordi-
nated mechanisms exist to regulate the two genomes and
determine the overall oxidative capacity (Kelly and Scarpulla,
2004). Peroxisome proliferator-activated receptor-γ (PPARγ)
coactivator-1α (PGC-1α) is an integrator of the molecular
regulatory circuit involved in the transcriptional control of
cellular energy metabolism, including mitochondrial biogene-
sis, hepatic gluconeogenesis, and fatty acid β-oxidation
(Puigserver and Spiegelman, 2003). PGC-1α serves as a direct
transcriptional coactivator of nuclear and non-nuclear receptor
transcription factors involved in cellular energy metabolism,
such as PPARγ and nuclear respiratory factors (NRFs) (Kelly
and Scarpulla, 2004). The interplay between NRFs and PGC-1
plays an important role in the physiological control of
respiratory chain proteins expression (Wu et al., 1999). NRFs
also regulate mitochondrial transcription factor A (Tfam), a
nuclearly encoded factor that translocates to mitochondria and
activates its replication and transcription (Virbasius and
Scarpulla, 1994).
Reduced expression of oxidative phosphorylation genes has
been observed in type 2 diabetes (Mootha et al., 2003),
accompanied by decreased expression of PGC-1α in prediabetic
and diabetic muscle (Patti et al., 2003). Additionally, changes
observed in the expression of nuclear-encoded mitochondrial
proteins correlate functional and morphological changes in the
mitochondria in various states of insulin resistance. Insulin
resistance is associated with decreased protein content of the
ATP synthase β subunit (Hojlund et al., 2003). High-fat diet,
which leads to insulin resistance due to increased concentrations
of free fatty acids, downregulates PGC-1α mRNA and genes
encoding proteins for complexes I, II, III, and IV (Sparks et al.,
2005). PGC-1α, both mRNA and protein, is also significantly
reduced in adipose tissue of insulin-resistant subjects (Hammar-
stedt et al., 2003). Taken together, the results suggest that
decreased PGC-1α expression may be responsible for decreased
expression of NRF-dependent genes. This may contribute to the
metabolic disturbances characteristic of insulin resistance and
diabetes mellitus.
Diabetic heart failure may be causally associated with
alterations in cardiac energy metabolism. Fuel selection and
capacity for ATP production in the normal and failing heart are
dictated by several metabolic regulatory events at the level of
gene expression. Decline in the capacity for ATP production
caused by progressive impairment of mitochondrial function is
a gradual step in the progression to heart failure of any cause.
Fetal heart depends on glucose and the adult heart on glucose
and fatty acids. The switch between fatty acid oxidation and
glucose on the adult heart leads to a healthy metabolic situation
(Huss and Kelly, 2005). In the insulin-resistant and diabetic
heart, fatty acid oxidation is increased and glucose utilization is
173A.P. Rolo, C.M. Palmeira / Toxicology and Applied Pharmacology 212 (2006) 167–178diminished. Long-term consequence of fatty acid oxidation is
mitochondrial dysfunction. A number of mechanisms may be
responsible for enhanced fatty acid utilization in type 2 diabetic
hearts such as increased fatty acid uptake into the cell and
mitochondria, increased UCP-3 expression, and stimulation of
peroxisome proliferator-activated receptor-α (PPARα). Dysre-
gulation of PPARα and its control of cardiac fatty acid
utilization have been detected in several cardiomyopathic
disease states (Carley and Severson, 2005). This chronic
activation of PPARα in the heart has several metabolic and
functional consequences. PPARα, along with its coactivator
PGC-1, has a role in the regulation of fatty acid oxidation,
mitochondrial biogenesis, and ATP production (Ram, 2003).
Mice that express constitutively PPARα show increased fatty
acid uptake and oxidation similarly to the diabetic heart. A
reduction in glucose utilization with cardiac insulin resistance is
also characteristic (Park et al., 2005). Cardiac-specific induction
of PGC-1α leads to increased mitochondrial biogenesis, with
ultrastructural derangements (Russell et al., 2004), coincident
with signs of mitochondrial oxidative stress reported in hearts of
mice with life-long type 1 diabetes. These data indicate that
chronic activation of PGC-1α and/or PPARα in diabetic heart
plays a role in the development of mitochondrial and
myocardial dysfunction.
β-cell insulin secretion and mitochondrial function
In pancreatic β-cells, the ATP/ADP ratio determines the
opening probability of the KATP channel involved in insulin
secretion. Changes in this ratio as a result of mitochondrial
dysfunction will affect the setting of the glucose-induced insulin
secretion response (Lowell and Shulman, 2005).
Glucose is transported across the cellular membrane by
glucose transporters (GLUT) mainly by GLUT-1. Glycolysis
transforms glucose to pyruvate, of which more than 90% is
shuttled into the mitochondria. The ratio of ATP/ADP increases
as processing of the glucose through glycolysis, TCA cycle, and
oxidative phosphorylation increases. This increase in ATP/ADP
ratio causes the ATP-sensitive K+ channels to close, causing
depolarization of voltage-sensitive Ca2+ channel, triggering the
exocytosis of insulin secretory vesicles (Maechler and Woll-
heim, 2001).
The critical importance of oxidative phosphorylation in
glucose-stimulated insulin secretion has been demonstrated by
several in vitro studies. Specific inhibitors of the complexes
of the mitochondrial respiratory chain were all found to
inhibit insulin release from pancreatic islet cells (MacDonald
and Fahien, 1990). Cells lacking mtDNA (rho0 cells) also
loose their ability to progressive enhancement of insulin
secretion by glucose stimulation. These cells depleted of
mtDNA have disproportionate changes in the nuclear-to-
mitochondrial composition of electron transport complexes
and a loss of respiratory efficiency, relying on glycolysis for
ATP production. Repopulation of rho0 cells with foreign
mtDNA restores the property of glucose-stimulated insulin
secretion (Soejima et al., 1996). This suggests that mtDNA
and the mitochondrial respiratory function are necessary forglucose-stimulated insulin secretion. β-cell pathology of
human mitochondrial diabetes has been reproduced in
Tfam-mutant mice. These animals, which have knockout of
the nuclear gene Tfam in pancreatic β-cell, develop diabetes,
with impaired insulin secretion and beta-cell loss. Tfam-
mutant mice also display severe mtDNA depletion, deficient
oxidative phosphorylation, and abnormal-appearing mitochon-
dria. Tfam is a transcriptional activator imported to
mitochondria, where it is essential for mtDNA expression
and maintenance. This animal model provides genetic
evidence for a critical role of the respiratory chain in insulin
secretion and β-cell function (Silva et al., 2000).
Chronic exposure of the β-cell to supraphysiologic
concentrations of glucose causes defective insulin gene
expression accompanied by marked decreases in insulin
content and abnormal insulin secretion (Robertson et al.,
1992, 2003). Hyperglycemia-induced superoxide production
by mitochondria is an important aspect in β-cell glucose
toxicity (Brownlee, 2003; Lowell and Shulman, 2005). The
link is the subsequent activation of UCP-2 by superoxide
(Krauss et al., 2003), with ROS leading to irreversible
decreases in the level of the transcription factor PDX-1,
critical for insulin gene expression (Robertson et al., 2003).
Furthermore, activation of UCP-2 by superoxide also
decreases the ATP/ADP ratio and thus reduces the insulin
secretory response (Lowell and Shulman, 2005). Aging-
related processes probably contribute to the gradual deterio-
ration of β-cell function (Maassen et al., 2004). Indeed,
insulin resistance is a major factor in the pathogenesis of type
2 diabetes in the elderly, associated with decreased mito-
chondrial oxidative phosphorylation activity. This indicates an
association between age-related decline in mitochondrial
function and insulin resistance (Petersen et al., 2003). The
mitochondrial theory of aging postulates that increased ROS
production, mtDNA damage accumulation, and progressive
respiratory chain dysfunction are mechanisms by which
mitochondria contribute to the aging process. A recent
study of genetically manipulated mice provided evidence
that such alterations may play a causal role in aging (Dufour
and Larsson, 2004).
New therapeutic targets
Treatment strategies that focus on decreasing oxidative stress
(Ceriello, 2003; Green et al., 2004) as well as enhancing
mitochondrial function might present important options for
diabetes treatment (Table 1). Coenzyme Q10 has shown some
clinical significance in a number of clinical trials. However, it
has failed to show consistent clinical benefit (Lamson and
Plaza, 2002). Coenzyme Q10 administration to GK rats showed
no success in preventing mitochondrial dysfunction (Oliveira et
al., 2004). The ineffectiveness of currently existing antioxidants
in ameliorating oxidative-stress-mediated diseases points to the
considerable interest in developing mitochondria-targeted
antioxidants. Triphenylphosphonium-based and amino-acid-
and peptide-based antioxidants have been shown to protect
mitochondria against oxidative insult, indicating that
Table 1
Therapeutic strategies in diabetes
Target Strategy Observations References
ROS Target antioxidants to
mitochondria to modulate
ROS production
CCCP decreases ROS production in bovine
aortic endothelial cells exposed to high glucose
Palmeira et al., 2001; Santos et al., 2001;
Bonnefont-Rousselot, 2002; Lamson and Plaza, 2002;
Nishikawa et al., 2002a, 2002b; Ceriello, 2003;
Maritim et al., 2003; Sheu et al., 2005
Decreased susceptibility of liver mitochondria
isolated from GK rats to oxidative damage
correlated with increased mitochondrial
vitamin E content
Triphenylphosphonium-based and amino-acid-
and peptide-based antioxidants have been
shown to protect mitochondria against
oxidative insult.
AGEs Prevention or slow AGEs
formation and reversal AGE
cross-links between proteins
Partial prevention by AGE inhibitors of
diabetic complications in animal models
Hammes et al., 1991; Soulis-Liparota et al., 1991;
Nakamura et al., 1997; Voziyan and Hudson, 2005
Inhibition of glycation reactions and AGEs
formation by pyridoxamine
PARP Prevention of NAD+ depletion
and glyceraldehyde-3-
phosphate dehydrogenase
inhibition
Inhibition of PARP protects against diabetic
cardiovascular dysfunction in preclinical models
Pacher and Szabo, 2005; Szabo, 2005;
Woon and Threadgill, 2005
Hyperglycemia-induced activation of PKC
isoforms, hexosaminase pathway flux,
and AGE formation is prevented by blocking
PARP activity
PPARγ and UCPs Modulation of PPARγ and
UCPs expression by TZD
Pioglitazone upregulates UCP-2 gene expression
in skeletal muscle of hyperglycemic KK mice
Shimabukuro et al., 1997; Fukui et al., 2000;
Ito et al., 2004
NC-2100 activates PPARγ in vivo and induces
expression of UCP-2 in isolated pancreatic islets
PPARγ overexpression induces
UCP-2 protein expression
FXR Modulation of lipid metabolism
and hepatic gluconeogenesis
FXR expression is reduced in diabetic rat models.
Administration of insulin to STZ-induced diabetic
rats restores FXR mRNA to normal levels
Duran-Sandoval et al., 2005; Suh et al., 2004
SHP positively regulates glucose-stimulated
insulin secretion in β-cells and restores
glucose sensitivity in UCP2-overexpressing β-cells
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disease treatment (Sheu et al., 2005).
Research into AGEs has been conducted with the goal to
unravel prospective pharmacological agents for preventing or
treating diabetic complications. The goals are to prevent or slow
AGEs formation and break the AGE cross-links between
proteins and possibly reverse the damage. The potential
importance of AGEs in the pathogenesis of diabetic complica-
tions has been shown by the partial prevention of two
structurally unrelated AGE inhibitors in various functional
and structural manifestations of diabetic disease in animal
models (Hammes et al., 1991; Soulis-Liparota et al., 1991;
Nakamura et al., 1997). Pyridoxamine has also been shown to
inhibit glycation reactions and the formation of AGEs (Voziyan
and Hudson, 2005). Pharmacological agents have been placed
in clinical trials to combat AGE processes in man. Pimagedine,
which inhibits AGEs formation in experimental models, did not
demonstrate a statistically significant beneficial effect on the
progression of nephropathy resulting from type 1 diabetes
(Bolton et al., 2004).
Experimental evidence implicates poly(ADP-ribose) poly-
merase (PARP) as a causative factor in the pathogenesis of
diabetes and diabetic complications, such as acute endothelial
dysfunction (Szabo, 2005). PARP catalyzes the transfer of
ADP-ribose units from the substrate NAD+ to acceptorproteins, biosynthesizing polyanionic poly(ADP-ribose) poly-
mers. Hyperglycemia-induced ROS overproduction leads to
DNA strand breakage and subsequent PARP activation. This
initiates an energy-consuming, inefficient cellular metabolic
cycle, which leads to NAD+ depletion and slows the rate of
glycolysis, electron transport, and ATP formation. Addition-
ally, it inhibits glyceraldehyde-3-phosphate dehydrogenase by
poly(ADP-ribosy)lation (Pacher and Szabo, 2005). PARP also
promotes the activation of various pro-inflammatory signal
transduction pathways. The therapeutic potential of PARP
inhibition in the prevention or reversal of diabetic complica-
tions has been the subject of intensive research work, but only
recently PARP inhibitors entered clinical trial (Woon and
Threadgill, 2005).
Recent developments concerning a novel thiazolidinedione
class of insulin-sensitizing agents represent a significant
advance in antidiabetic therapy. This class of drugs activates
peroxisome proliferator-activated receptors, which play a
central role in regulating the storage and catabolism of dietary
fats (Ram, 2003; Kota et al., 2005). PPARγ is the major
molecular target for the insulin-sensitizing thiazolidinedione
(TZD) drugs. PPARγ has been shown to modulate the
transcription activities of a great number of genes involved in
energy storage and utilization, including the mitochondrial
uncoupling proteins, UCP-1, UCP-2, and UCP-3 (Kelly et al.,
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stimulate UCP-2 expression in different cell lines (Camirand et
al., 1998; Hammarstedt and Smith, 2003). More specifically,
pioglitazone has been shown to upregulate UCP-2 gene
expression in skeletal muscle of hyperglycemic KK mice
(Shimokawa et al., 1998), as well as troglitazone in pancreatic
islets of Zucker diabetic fatty rats (Shimabukuro et al., 1997).
Fukui and colleagues showed that NC-2100, a novel thiazoli-
dinedione, activates PPARγ in vivo and induces expression of
UCP-2 in white adipose tissue (Fukui et al., 2000). More
recently, Ito and colleagues showed that in isolated pancreatic
islets PPARγ overexpression induced UCP-2 protein expres-
sion (Ito et al., 2004). In this respect, PPARγ appears to be of
promising pharmacological interest since it was identified as the
target of TZDs used in the treatment of non-insulin-dependent
diabetes mellitus (Olefsky, 2000; Ram, 2003).
Another potential therapeutic target is the farnesoid X
receptor (FXR), a nuclear hormone receptor that functions as
the bile acid receptor. In addition to the critical role that FXR
plays in bile acid metabolism and transport, it regulates a variety
of genes important in lipid metabolism (De Fabiani et al., 2004;
Claudel et al., 2005). The first indication of a potential role for
FXR in diabetes and the metabolic syndrome comes from the
observation that hepatic FXR expression is reduced in diabetic
rat models and that administration of insulin to STZ-induced
diabetic rats restored FXR mRNA to normal levels. It has been
demonstrated that FXR expression is regulated by glucose via
the pentose phosphate pathway and suggested that alterations of
FXR expression in diabetics may contribute to dysregulation of
lipid and bile acid metabolism (Duran-Sandoval et al., 2005).
Hepatic gluconeogenesis is significantly increased in type 2
diabetics, contributing to the observed fasting hyperglycemia.
Pharmacological inhibition of this pathway has been proposed
as a method to restore insulin sensitivity, which has been
validated by the antidiabetic drug metformin, that reduces
hepatic glucose production via inhibition of gluconeogenesis
(Barthel and Schmoll, 2003). One pivotal point of regulation of
the gluconeogenesis pathway is the expression of phospho-
enolpyruvate carboxykinase (PEPCK), suggesting a potential
point of pharmacological intervention. FXR plays a role in
carbohydrate metabolism via regulation of PEPCK gene
expression (Stayrook et al., 2005). FXR participates in the
regulation of the fasting-induced gluconeogenic response via
induction of the small heterodimer partner (SHP). SHP is an
orphan nuclear receptor whose function in pancreatic β-cells is
unclear. SHP positively regulates glucose-stimulated insulin
secretion in β-cells and restores glucose sensitivity in UCP2-
overexpressing β-cells by enhancing mitochondrial glucose
metabolism (Suh et al., 2004).
Conclusion
Hyperglycemia elicits an increase in ROS production,
presumably from the mitochondrial respiratory chain. ROS
plays a central role in mediating various metabolic defects
associated with the diabetic state. Therefore, inhibition of
ROS production and/or enhancement of ROS scavenging willprove to be beneficial therapies. Damage to mtDNA has been
shown in certain situations to result in the type 2 diabetes
phenotype. Another aspect of dysfunction is associated with
the quantitative reduction in mtDNA copy number. Altera-
tions in metabolic regulators and glucose-stimulated insulin
secretion are also associated with mitochondrial dysfunction
in diabetes.
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